Immunoglobulin E Explained

Immunoglobulin E (IgE) is a type of antibody (or immunoglobulin (Ig) "isotype") that has been found only in mammals. IgE is synthesised by plasma cells. Monomers of IgE consist of two heavy chains (ε chain) and two light chains, with the ε chain containing four Ig-like constant domains (Cε1–Cε4).[1] IgE is thought to be an important part of the immune response against infection by certain parasitic worms, including Schistosoma mansoni, Trichinella spiralis,[2] [3] and Fasciola hepatica.[4] IgE is also utilized during immune defense against certain protozoan parasites such as Plasmodium falciparum.[5] IgE may have evolved as a defense to protect against venoms.[6]

IgE also has an essential role in type I hypersensitivity,[7] which manifests in various allergic diseases, such as allergic asthma, most types of sinusitis, allergic rhinitis, food allergies, and specific types of chronic urticaria and atopic dermatitis. IgE also plays a pivotal role in responses to allergens, such as: anaphylactic reactions to drugs, bee stings, and antigen preparations used in desensitization immunotherapy.

IgE is typically the least abundant isotype: blood serum IgE levels in a non-atopic individual are only 0.05% of the Ig concentration,[8] compared to 75% for the IgGs at 10 mg/ml. Despite this, it is capable of triggering anaphylaxis, one of the most rapid and severe immunological reactions.[9]

__TOC__

Discovery

IgE was simultaneously discovered in 1966 and 1967 by two independent groups:[10] Kimishige Ishizaka and his wife Teruko Ishizaka at the Children's Asthma Research Institute and Hospital in Denver, Colorado,[11] and by Gunnar Johansson and in Uppsala, Sweden.[12] Their joint paper was published in April 1969.[13]

Receptors

IgE primes the IgE-mediated allergic response by binding to Fc receptors found on the surface of mast cells and basophils. Fc receptors are also found on eosinophils, monocytes, macrophages and platelets in humans. There are two types of Fcε receptors:

IgE can upregulate the expression of both types of Fcε receptors. FcεRI is expressed on mast cells, basophils, and the antigen-presenting dendritic cells in both mice and humans. Binding of antigens to IgE already bound by the FcεRI on mast cells causes cross-linking of the bound IgE and the aggregation of the underlying FcεRI, leading to degranulation (the release of mediators) and the secretion of several types of type 2 cytokines like interleukin (IL)-3 and stem cell factor (SCF), which both help the mast cells survive and accumulate in tissue, and IL-4, IL-5, IL-13, and IL-33, which in turn activate group 2-innate lymphoid cells (ILC2 or natural helper cells). Basophils share a common haemopoietic progenitor with mast cells; upon the cross-linking of their surface bound IgE by antigens, also release type 2 cytokines, including IL-4 and IL-13, and other inflammatory mediators. The low-affinity receptor (FcεRII) is always expressed on B cells; but IL-4 can induce its expression on the surfaces of macrophages, eosinophils, platelets, and some T cells.[14] [15]

Function

Parasite hypothesis

The IgE isotype has co-evolved with basophils and mast cells in the defence against parasites like helminths (like Schistosoma) but may be also effective in bacterial infections.[16] Epidemiological research shows that IgE level is increased when infected by Schistosoma mansoni,[17] Necator americanus,[18] and nematodes[19] in humans. It is most likely beneficial in removal of hookworms from the lung.

Toxin hypothesis of allergic disease

In 1981 Margie Profet suggested that allergic reactions have evolved as a last line of defense to protect against venoms.[20] Although controversial at the time, new work supports some of Profet’s thoughts on the adaptive role of allergies as a defense against noxious toxins.[21]

In 2013 it emerged that IgE-antibodies play an essential role in acquired resistance to honey bee and Russell's viper venoms.[22] The authors concluded that "a small dose of bee venom conferred immunity to a much larger, fatal dose" and "this kind of venom-specific, IgE-associated, adaptive immune response developed, at least in evolutionary terms, to protect the host against potentially toxic amounts of venom, such as would happen if the animal encountered a whole nest of bees, or in the event of a snakebite".[23] [24] The major allergen of bee venom (phospholipase A2) induces a Th2 immune responses, associated with production of IgE antibodies, which may "increase the resistance of mice to challenge with potentially lethal doses".[25]

Cancer

Although it is not yet well understood, IgE may play an important role in the immune system's recognition of cancer,[26] in which the stimulation of a strong cytotoxic response against cells displaying only small amounts of early cancer markers would be beneficial. If this were the case, anti-IgE treatments such as omalizumab (for allergies) might have some undesirable side effects. However, a recent study, which was performed based on pooled analysis using comprehensive data from 67 phase I to IV clinical trials of omalizumab in various indications, concluded that a causal relationship between omalizumab therapy and malignancy is unlikely.[27]

Role in disease

Atopic individuals can have up to ten times the normal level of IgE in their blood (as do sufferers of hyper-IgE syndrome). However, this may not be a requirement for symptoms to occur as has been seen in asthmatics with normal IgE levels in their blood—recent research has shown that IgE production can occur locally in the nasal mucosa.[28]

IgE that can specifically recognise an allergen (typically this is a protein, such as dust mite Der p 1, cat Fel d 1, grass or ragweed pollen, food protein, etc.) has a unique long-lived interaction with its high-affinity receptor FcεRI so that basophils and mast cells, capable of mediating inflammatory reactions, become "primed", ready to release chemicals like histamine, leukotrienes, and certain interleukins. These chemicals cause many of the symptoms we associate with allergy, such as airway constriction in asthma, local inflammation in eczema, increased mucus secretion in allergic rhinitis, and increased vascular permeability, it is presumed, to allow other immune cells to gain access to tissues, but which can lead to a potentially fatal drop in blood pressure as in anaphylaxis.

IgE is known to be elevated in various autoimmune disorders such as SLE, rheumatoid arthritis (RA), and psoriasis, and is theorized to be of pathogenetic importance in SLE and RA by eliciting a hypersensitivity reaction.[29] [30]

Regulation of IgE levels through control of B cell differentiation to antibody-secreting plasma cells is thought to involve the "low-affinity" receptor FcεRII, or CD23.[31] CD23 may also allow facilitated antigen presentation, an IgE-dependent mechanism whereby B cells expressing CD23 are able to present allergen to (and stimulate) specific T helper cells, causing the perpetuation of a Th2 response, one of the hallmarks of which is the production of more antibodies.[32]

Role in diagnosis

Diagnosis of allergy is most often done by reviewing a person's medical history and finding a positive result for the presence of allergen specific IgE when conducting a skin or blood test.[33] Specific IgE testing is the proven test for allergy detection; evidence does not show that indiscriminate IgE testing or testing for immunoglobulin G (IgG) can support allergy diagnosis.[34]

Drugs targeting the IgE pathway

Currently, allergic diseases and asthma are usually treated with one or more of the following drugs: (1) antihistamines and antileukotrienes, which antagonize the inflammatory mediators histamine and leukotrienes, (2) local or systemic (oral or injectable) corticosteroids, which suppress a broad spectrum of inflammatory mechanisms, (3) short or long-acting bronchodilators, which relax smooth muscle of constricted airway in asthma, or (4) mast cell stabilizers, which inhibit the degranulation of mast cells that is normally triggered by IgE-binding at FcεRI. Long-term uses of systemic corticosteroids are known to cause many serious side effects and are advisable to avoid, if alternative therapies are available.

IgE, the IgE synthesis pathway, and the IgE-mediated allergic/inflammatory pathway are all important targets in intervening with the pathological processes of allergy, asthma, and other IgE-mediated diseases. The B lymphocyte differentiation and maturation pathway that eventually generate IgE-secreting plasma cells go through the intermediate steps of IgE-expressing B lymphoblasts and involves the interaction with IgE-expressing memory B cells. Tanox, a biotech company based in Houston, Texas, proposed in 1987 that by targeting membrane-bound IgE (mIgE) on B lymphoblast and memory B cells, those cells can be lysed or down-regulated, thus achieving the inhibition of the production of antigen-specific IgE and hence a shift of immune balance toward non-IgE mechanisms.[35] Two approaches targeting the IgE pathway were evolved and both are in active development. In the first approach, the anti-IgE antibody drug omalizumab (trade name Xolair) recognises IgE not bound to its receptors and is used to neutralise or mop-up existing IgE and prevent it from binding to the receptors on mast cells and basophils. Xolair has been approved in many countries for treating severe, persistent allergic asthma. It has also been approved in March 2014 in the European Union[36] and the U. S.[37] for treating chronic spontaneous urticaria, which cannot be adequately treated with H1-antihistamines. In the second approach, antibodies specific for a domain of 52 amino acid residues, referred to as CεmX or M1’ (M1 prime), present only on human mIgE on B cells and not on free, soluble IgE, have been prepared and are under clinical development for the treatment of allergy and asthma.[38] [39] An anti-M1’ humanized antibody, quilizumab, is in phase IIb clinical trial.[40] [41]

In 2002, researchers at the Randall Division of Cell and Molecular Biophysics determined the structure of IgE.[42] Understanding of this structure (which is atypical of other isotypes in that it is highly bent and asymmetric) and of the interaction of IgE with receptor FcεRI will enable development of a new generation of allergy drugs that seek to interfere with the IgE-receptor interaction. It may be possible to design treatments cheaper than monoclonal antibodies (for instance, small molecule drugs) that use a similar approach to inhibit binding of IgE to its receptor.

Notes and References

  1. Web site: Antibody structure . dead . https://web.archive.org/web/20080906211232/http://www.cartage.org.lb/en/themes/Sciences/LifeScience/GeneralBiology/Immunology/Recognition/AntigenRecognition/Antibodystructure/Antibodystructure.htm . September 6, 2008.
  2. Erb KJ . Helminths, allergic disorders and IgE-mediated immune responses: where do we stand? . European Journal of Immunology . 37 . 5 . 1170–3 . May 2007 . 17447233 . 10.1002/eji.200737314 . 24519249 . free .
  3. Watanabe N, Bruschi F, Korenaga M . IgE: a question of protective immunity in Trichinella spiralis infection . Trends in Parasitology . 21 . 4 . 175–8 . April 2005 . 15780839 . 10.1016/j.pt.2005.02.010 .
  4. Pfister K, Turner K, Currie A, Hall E, Jarrett EE . IgE production in rat fascioliasis . Parasite Immunology . 5 . 6 . 587–93 . November 1983 . 6657297 . 10.1111/j.1365-3024.1983.tb00775.x . 1530964 .
  5. Duarte J, Deshpande P, Guiyedi V, Mécheri S, Fesel C, Cazenave PA, Mishra GC, Kombila M, Pied S . 6 . Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical status . Malaria Journal . 6 . 1 . January 2007 . 17204149 . 1781948 . 10.1186/1475-2875-6-1 . free .
  6. Marichal T, Starkl P, Reber LL, Kalesnikoff J, Oettgen HC, Tsai M, Metz M, Galli SJ . 6 . A beneficial role for immunoglobulin E in host defense against honeybee venom . en . Immunity . 39 . 5 . 963–75 . November 2013 . 24210352 . 4164235 . 10.1016/j.immuni.2013.10.005 .
  7. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L . 6 . The biology of IGE and the basis of allergic disease . Annual Review of Immunology . 21 . 579–628 . 2003 . 12500981 . 10.1146/annurev.immunol.21.120601.141103 .
  8. Winter WE, Hardt NS, Fuhrman S . Immunoglobulin E: importance in parasitic infections and hypersensitivity responses . Archives of Pathology & Laboratory Medicine . 124 . 9 . 1382–5 . September 2000 . 10975945 . 10.5858/2000-124-1382-IE .
  9. Reber . LL . Hernandez . JD . Galli . SJ . The pathophysiology of anaphylaxis. . The Journal of Allergy and Clinical Immunology . August 2017 . 140 . 2 . 335–348 . 10.1016/j.jaci.2017.06.003 . 28780941 . 5657389.
  10. Stanworth DR . The discovery of IgE . Allergy . 48 . 2 . 67–71 . February 1993 . 8457034 . 10.1111/j.1398-9995.1993.tb00687.x . 36262710 . free .
  11. Ishizaka K, Ishizaka T, Hornbrook MM . Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity . Journal of Immunology . 97 . 1 . 75–85 . July 1966 . 10.4049/jimmunol.97.1.75 . 4162440 . 255620017 . free .
  12. Johansson SG, Bennich H . Immunological studies of an atypical (myeloma) immunoglobulin . Immunology . 13 . 4 . 381–94 . October 1967 . 4168094 . 1409218 .
  13. Ishizaka T, Ishizaka K, Johansson SG, Bennich H . Histamine release from human leukocytes by anti-gamma E antibodies . Journal of Immunology . 102 . 4 . 884–92 . April 1969 . 10.4049/jimmunol.102.4.884 . 4181251 . 255338552 . 2016-02-29 . free .
  14. Ewart MA, Ozanne BW, Cushley W . The CD23a and CD23b proximal promoters display different sensitivities to exogenous stimuli in B lymphocytes . Genes and Immunity . 3 . 3 . 158–64 . May 2002 . 12070780 . 10.1038/sj.gene.6363848 . free .
  15. Novak N, Kraft S, Bieber T . IgE receptors . Current Opinion in Immunology . 13 . 6 . 721–6 . December 2001 . 11677096 . 10.1016/s0952-7915(01)00285-0 .
  16. Abraham . Soman N. . St. John . Ashley L. . June 2010 . Mast cell-orchestrated immunity to pathogens . Nature Reviews Immunology . en . 10 . 6 . 440–452 . 10.1038/nri2782 . 1474-1741 . 4469150 . 20498670.
  17. Rihet P, Demeure CE, Bourgois A, Prata A, Dessein AJ . Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels . European Journal of Immunology . 21 . 11 . 2679–86 . November 1991 . 1936116 . 10.1002/eji.1830211106 . 1103861 .
  18. Pritchard DI, Quinnell RJ, Walsh EA . Immunity in humans to Necator americanus: IgE, parasite weight and fecundity . Parasite Immunology . 17 . 2 . 71–5 . February 1995 . 7761110 . 10.1111/j.1365-3024.1995.tb00968.x . 41222700 .
  19. Turner JD, Faulkner H, Kamgno J, Kennedy MW, Behnke J, Boussinesq M, Bradley JE . Allergen-specific IgE and IgG4 are markers of resistance and susceptibility in a human intestinal nematode infection . Microbes and Infection . 7 . 7–8 . 990–6 . June 2005 . 15961339 . 10.1016/j.micinf.2005.03.036 . 1 . free .
  20. Profet M . The function of allergy: immunological defense against toxins . The Quarterly Review of Biology . 66 . 1 . 23–62 . March 1991 . 2052671 . 10.1086/417049 . 5648170 .
  21. Palm NW, Rosenstein RK, Medzhitov R . Allergic host defences . Nature . 484 . 7395 . 465–72 . April 2012 . 22538607 . 3596087 . 10.1038/nature11047 . 2012Natur.484..465P .
  22. Starkl P, Marichal T, Gaudenzio N, Reber LL, Sibilano R, Tsai M, Galli SJ . IgE antibodies, FcεRIα, and IgE-mediated local anaphylaxis can limit snake venom toxicity . The Journal of Allergy and Clinical Immunology . 137 . 1 . 246–257.e11 . January 2016 . 26410782 . 4715494 . 10.1016/j.jaci.2015.08.005 .
  23. Web site: Bee sting allergy could be a defense response gone haywire, scientists say. Sharlach. Molly. 24 October 2013. Stanford Medicine News Center. 20 November 2019.
  24. Web site: Severe Allergies to Bee Stings may be Malfunctioning Evolutionary Response. Foley. James A.. 25 October 2013. Nature World News.
  25. Tsai M, Starkl P, Marichal T, Galli SJ . Testing the 'toxin hypothesis of allergy': mast cells, IgE, and innate and acquired immune responses to venoms . Current Opinion in Immunology . 36 . 80–7 . October 2015 . 26210895 . 4593748 . 10.1016/j.coi.2015.07.001 .
  26. Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ . 6 . Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells . European Journal of Immunology . 33 . 4 . 1030–40 . April 2003 . 12672069 . 10.1002/eji.200323185 . 29495137 .
  27. Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, Canvin J . Omalizumab and the risk of malignancy: results from a pooled analysis . The Journal of Allergy and Clinical Immunology . 129 . 4 . 983–9.e6 . April 2012 . 22365654 . 10.1016/j.jaci.2012.01.033 .
  28. Takhar P, Smurthwaite L, Coker HA, Fear DJ, Banfield GK, Carr VA, Durham SR, Gould HJ . 6 . Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis . Journal of Immunology . 174 . 8 . 5024–32 . April 2005 . 15814733 . 10.4049/jimmunol.174.8.5024 . free .
  29. Permin H, Wiik A . The prevalence of IgE antinuclear antibodies in rheumatoid arthritis and systemic lupus erythematosus . Acta Pathologica et Microbiologica Scandinavica, Section C . 86C. 5 . 245–9 . October 1978 . 309705 . 10.1111/j.1699-0463.1978.tb02587.x . 13737751 .
  30. Elkayam O, Tamir R, Pick AI, Wysenbeek A . Serum IgE concentrations, disease activity, and atopic disorders in systemic lupus erythematosus . Allergy . 50 . 1 . 94–6 . January 1995 . 7741196 .
  31. Conrad DH, Ford JW, Sturgill JL, Gibb DR . CD23: an overlooked regulator of allergic disease . Current Allergy and Asthma Reports . 7 . 5 . 331–7 . September 2007 . 17697638 . 10.1007/s11882-007-0050-y . 24816595 .
  32. Holm J, Willumsen N, Würtzen PA, Christensen LH, Lund K . Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity . The Journal of Allergy and Clinical Immunology . 127 . 4 . 1029–37 . April 2011 . 21377718 . 10.1016/j.jaci.2011.01.062 .
  33. Cox L, Williams B, Sicherer S, Oppenheimer J, Sher L, Hamilton R, Golden D . Pearls and pitfalls of allergy diagnostic testing: report from the American College of Allergy, Asthma and Immunology/American Academy of Allergy, Asthma and Immunology Specific IgE Test Task Force . Annals of Allergy, Asthma & Immunology . 101 . 6 . 580–92 . December 2008 . 19119701 . 10.1016/S1081-1206(10)60220-7 .
  34. American Academy of Allergy, Asthma, and Immunology . American Academy of Allergy, Asthma, and Immunology . Five Things Physicians and Patients Should Question . Choosing Wisely: An Initiative of the ABIM Foundation . August 14, 2012 . dead . https://web.archive.org/web/20121103151124/http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_AAAAI.pdf . November 3, 2012 .
  35. Book: Chang TW, Wu PC, Hsu CL, Hung AF . Anti‐IgE Antibodies for the Treatment of IgE‐Mediated Allergic Diseases . 93 . 63–119 . 2007 . 17383539 . 10.1016/S0065-2776(06)93002-8 . 9780123737076 . Advances in Immunology .
  36. Web site: Novartis announces Xolair® approved in EU as first and only licensed therapy for chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines . 2014-03-06 . Novartis . 2014-12-04 . https://web.archive.org/web/20141218194127/http://www.novartis.com/newsroom/media-releases/en/2014/1766627.shtml . 2014-12-18 . dead .
  37. Web site: Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria (CIU) . 2014-03-21 . Novartis . 2014-12-04 . https://web.archive.org/web/20141203150646/http://www.novartis.com/newsroom/media-releases/en/2014/1770973.shtml . 2014-12-03 . dead .
  38. Chen JB, Wu PC, Hung AF, Chu CY, Tsai TF, Yu HM, Chang HY, Chang TW . 6 . Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells . Journal of Immunology . 184 . 4 . 1748–56 . February 2010 . 20083663 . 10.4049/jimmunol.0902437 . Howard Y. Chang . free .
  39. Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, Nguyen A, Yeh S, Delarosa D, Leong SR, Wong T, Chen Y, Ultsch M, Luis E, Ramani SR, Jackman J, Gonzalez L, Dennis MS, Chuntharapai A, DeForge L, Meng YG, Xu M, Eigenbrot C, Lee WP, Refino CJ, Balazs M, Wu LC . 6 . Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice . The Journal of Clinical Investigation . 120 . 6 . 2218–29 . June 2010 . 20458139 . 2877936 . 10.1172/JCI40141 .
  40. Web site: MEMP1972A . . ClinicalTrials.gov . 2014-12-04.
  41. Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM . 6 . Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production . Science Translational Medicine . 6 . 243 . 243ra85 . July 2014 . 24990880 . 10.1126/scitranslmed.3008961 . 41593528 .
  42. Wan T, Beavil RL, Fabiane SM, Beavil AJ, Sohi MK, Keown M, Young RJ, Henry AJ, Owens RJ, Gould HJ, Sutton BJ . 6 . The crystal structure of IgE Fc reveals an asymmetrically bent conformation . Nature Immunology . 3 . 7 . 681–6 . July 2002 . 12068291 . 10.1038/ni811 . 32347451 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Immunoglobulin E".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.